CIBUS INC (CBUS) Stock Price, Quote, News and Overview
NASDAQ:CBUS - Nasdaq - US17166A1016 - Common Stock - Currency: USD
CBUS Quote, Performance and Key Statistics
CIBUS INC
NASDAQ:CBUS (1/27/2025, 11:05:24 AM)
2.34
-0.08 (-3.31%)
The current stock price of CBUS is 2.34 USD. In the past month the price decreased by -14.79%. In the past year, price decreased by -85.22%.
CBUS Latest News, Press Releases and Analysis
Cibus to Participate in the Sidoti Micro Cap Conference
Cibus to Participate in the Sidoti Micro Cap Conference
SAN DIEGO, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the “Company”), a leading agricultural biotechnology company that uses...
Sidoti Events, LLC's Virtual January Micro-Cap Conference
Cibus, Inc. Announces $22.6 Million Registered Direct Offering Priced Above Nasdaq’s Minimum Price in Accordance with Nasdaq Rules
SAN DIEGO, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the “Company” or “Cibus”), a leading agricultural biotechnology company that...
CBUS Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 16.23 | 308.30B | ||
| AMGN | AMGEN INC | 14.47 | 149.50B | ||
| GILD | GILEAD SCIENCES INC | 21.49 | 118.66B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 861.06 | 113.09B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.04 | 75.07B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.42B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 36.36B | ||
| BNTX | BIONTECH SE-ADR | N/A | 29.07B | ||
| ONC | BEIGENE LTD-ADR | N/A | 24.27B | ||
| NTRA | NATERA INC | N/A | 22.13B | ||
| BIIB | BIOGEN INC | 9.1 | 21.65B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 17.25B |
Related stock screener links
About CBUS
Company Profile
Cibus, Inc. engages in the research and development of plant traits to seed companies for royalties. The company is headquartered in San Diego, California and currently employs 183 full-time employees. The company went IPO on 2017-07-20. Its business is the development of plant traits that help address specific productivity or yield challenges in farming, such as traits addressing plant agronomy, disease, insects, weeds, nutrient-use, or the climate. The company is also engaged in developing, certain alternative plant-based oils or bio-based fermentation products. Its technology is its gene editing platform called the Rapid Trait Development System (RTDS). The company is the underlying technology in the Company's Trait Machine process, an end-to-end semi-automated high-throughput gene editing system that directly edits seed companies' elite germplasm. The company has a pipeline of five productivity traits, four of which are applicable to multiple crops. These traits are PSR in Canola and HT1 and HT3 in rice. In addition, it also has two advanced traits for Sclerotinia resistance and another novel broadleaf HT trait, HT2.
Company Info
CIBUS INC
6455 Nancy Ridge Drive
San Diego CALIFORNIA US
Employees: 183
Company Website: https://www.cibus.com/
Investor Relations: https://ir.calyxt.com/
Phone: 18584500008
CBUS FAQ
What is the stock price of CBUS?
The current stock price of CBUS is 2.34 USD.
What is the symbol for CIBUS INC stock?
The exchange symbol of CIBUS INC is CBUS and it is listed on the Nasdaq exchange.
On which exchange is CBUS stock listed?
CBUS stock is listed on the Nasdaq exchange.
Is CBUS a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for CBUS, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of CBUS.
Does CBUS stock pay dividends?
CBUS does not pay a dividend.
What is the Price/Earnings (PE) ratio of CBUS?
CBUS does not have a PE ratio as the earnings reported over the last twelve months were negative (-14.79).
What is the Short Interest ratio of CBUS stock?
The outstanding short interest for CBUS is 11.78% of its float.
CBUS Technical Analysis
CBUS Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CBUS. CBUS may be in some trouble as it scores bad on both profitability and health.
CBUS Financial Highlights
Over the last trailing twelve months CBUS reported a non-GAAP Earnings per Share(EPS) of -14.79. The EPS decreased by -12.99% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -121.07% | ||
| ROE | -411.87% | ||
| Debt/Equity | 0 |
CBUS Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 80% to CBUS. The Buy consensus is the average rating of analysts ratings from 10 analysts.
For the next year, analysts expect an EPS growth of 60.45% and a revenue growth 267.86% for CBUS